A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy

This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases refractory to standard therapy

NCT Number	NCT07341828
Lead Sponsor	Huashan Hospital Collaborators: Shanghai AbelZeta Ltd.
Conditions	Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome
Enrollment	15 participants
Start Date	2026-02
Primary Completion	2027-06 (estimated)
Study Completion	2029-02 (estimated)
Updated on ClinicalTrials.gov	2026-01-15